Novartis Option Fund licenses option on Viamet's metalloenzyme programme
This article was originally published in Scrip
Executive Summary
The Novartis Option Fund has signed a licensing option deal with the small US biotechnology firm Viamet Pharmaceuticals.
You may also be interested in...
IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle
Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.